Custom Criteria for
BlueCross Blue Shield of Rhode Island Commercial

XEOMIN ® (incobotulinumtoxinA)

GPI CODING:

74400020******

DESCRIPTION:

IncobotulinumtoxinA (XEOMIN®) is a botulinum neurotoxin product produced by the spore-forming anaerobic bacillus *Clostridium botulinum* type A. Botulinum toxins inhibit the release of acetylcholine from cholinergic junctions, causing functional denervation of the muscle that results in a localized reduction of muscle activity. Botulinum toxin type A products, like XEOMIN, specifically inhibit acetylcholine release by cleaving the synaptosomal-associated protein of 25-kilodaltons (SNAP-25), which is important for the successful binding and release of acetylcholine in the nerve endings. Recovery of transmission occurs gradually as the neuromuscular junction recovers from SNAP25 cleavage and as new nerve endings are formed.

APPROVAL DURATION:

Initial approvals and renewals: 12 months.

CRITERIA FOR XEOMIN

I. Patient has a diagnosis for one of the following:
   A. Blepharospasm **OR**
   B. Cervical dystonia (including spasmodic torticollis)

AND

II. Patient does not have any of the following contraindications to therapy:
   A. Hypersensitivity to human albumin or sucrose
   B. Presence of infection at the proposed injection site(s)

Authorization for continued use shall be reviewed at least every 12 months to confirm that current coverage policy criteria are met.